View Older Stories View More Recent Stories
-
Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Novo Nordisk (NVO) PT Lowered to $70 at TD Cowen
-
Novo Nordisk, Eli Lilly rise after Viking obesity trial data
-
Novo Nordisk's Ozempic gets Canadian approval for kidney disease
-
Mizuho Reiterates Neutral Rating on GoodRx Holdings Inc. (GDRX)
-
Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
-
BofA Securities Reiterates Underperform Rating on GoodRx Holdings Inc. (GDRX)
-
Active options: NVO BBAI CRWV MSTR AMZN BULL FSLR NIO GOOGL
-
GoodRx partners with Novo Nordisk to offer Ozempic, Wegovy for $499 monthly
-
Novo Nordisk (NVO) launches cash-pay Ozempic at $499/month, half the regular price
-
Novo Nordisk offers Ozempic at $499 monthly for uninsured patients
-
BMO Capital: 'Novo Nordisk (NVO) Takes a Step in the Right Direction'
-
BNP Paribas Exane Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
-
What to do with Novo Nordisk shares after recent volatility? Barclays explains
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
-
Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial
-
Novo Nordisk (NVO) call put ratio 2.3 calls to 1 put with a focus on August calls
-
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK355 at HSBC
-
Eli Lilly shares slip 7% premarket as weight-loss pill study overshadows earnings
-
BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk shares jump as Eli Lilly obesity pill disappoints
-
Novo Nordisk (NVO) PT Lowered to $50 at BMO Capital
-
Morgan Stanley Reiterates Overweight Rating on Akero Therapeutics (AKRO) (premarket)
-
Stocks expected to have increasing option volume: NVO LCID RNG DIS CPNG RIVN ABNB MCD DIS UBER SHOP ROK GPN DT U PLNT
-
Novo Nordisk (NVO) Reports 1H EPS of DKK12.49
-
Novo Nordisk earnings preview: Analysts cautious ahead of release
-
Novo Nordisk files 14 new lawsuits over compounded semaglutide drugs
-
Hims & Hers Health, Inc. (HIMS) on Watch; Novo Nordisk (NVO) Expands Legal Action to Protect US Patients From Non-FDA-approved Compounded 'Semaglutide'
-
UBS Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
-
Barclays on GLP-1s: 'we caution that price erosion across GLP-1 class could come faster and more deeply than we expected'
-
UBS' Quality and Growth Opportunities Screener yields 15 stocks
-
Novo Nordisk (NVO) stock: Where next after profit warning?
-
Novo Nordisk shares hit lowest level in over 3-years
-
Trump admin to pilot coverage of weight‑loss drugs under Medicare and Medicaid - WaPo
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
HSBC Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
-
BofA Securities Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
-
Barclays Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Equalweight
-
Novo Nordisk (NVO) PT Lowered to $55 at BMO Capital
-
Active options: NVDA SOFI AMD TSLA UNH SMCI OPEN PYPL NVO
-
Novo Nordisk cuts full-year sales and profit guidance, stock plunges
-
Novo Nordisk (NVO) appoints Maziar Mike Doustdar as CEO and President, Chief Scientific Officer Retires
-
Hims & Hers (HIMS) reportedly makes statement on congressional letter to FDA
-
Hims & Hers Health, Inc. (NYSE: HIMS) Falls, Group Of 81 Bipartisan Lawmakers Sign Letter On Glp-1 Action
-
Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Hims & Hers (HIMS) launches ads targeting patient personalization in newspapers
-
Novo Nordisk (NVO): New Wegovy dose submitted to European Medicines Agency for approval
-
Morgan Stanley on Compounder Lawsuits: 'experts think the courts would likely refuse to dismiss the case and that it could take 2-3 years to resolve'
-
WeightWatchers (WGHTQ) and Novo Nordisk (NVO) Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care
-
LifeMD (LFMD) stock rises on continued Wegovy partnership with Novo Nordisk (NVO)
